Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Aljosja RogiersInes Pires da SilvaChiara TentoriCarlo Alberto TondiniJoseph M GrimesMegan H TragerSharon H NahmLeyre ZubiriMichael ManosPeter BowlingArielle ElkriefNeha PapnejaMaria Grazia VitaleApril A N RoseJessica S W BorgersSeverine RoyJoanna ManganaThiago Pimentel MunizTim CooksleyJeremy LupuAlon VaismanSamuel D SaibilMarcus O ButlerAlexander M MenziesMatteo S CarlinoMichael ErdmannCarola BerkingLisa ZimmerDirk SchadendorfLaura PalaPaola QueiroloChristian PoschAxel HauschildReinhard DummerJohn HaanenChristian U BlankCaroline RobertRyan J SullivanPaolo Antonio AsciertoWilson H MillerF Stephen HodiKarijn P M SuijkerbuijkKerry L ReynoldsOsama E RahmaPaul C LoriganRichard D CarvajalSerigne N LôMario MandalaGeorgina V LongPublished in: Journal for immunotherapy of cancer (2021)
COVID-19-related mortality in the ICI-treated population does not appear to be higher than previously published mortality rates for patients with cancer. Inpatient mortality of patients with cancer treated with ICI was high in comparison with previously reported rates for hospitalized patients with cancer and was due to COVID-19 in almost half of the cases. We identified factors associated with adverse outcomes in ICI-treated patients with COVID-19.